Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: A phase 1 study

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 5, 2013, Pages

  Deenen, Maarten J ^a   Dewit, Luc ^a   Boot, Henk ^a   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c   Cats, Annemieke ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLETE RESPONSE; DOSE LIMITING TOXICITY; INGUINAL LYMPH NODES; MAXIMUM TOLERATED DOSE; METHODS AND MATERIALS; PARTIAL RESPONSE; RADIATION DERMATITIS; RESIDUAL TUMORS;

DISEASES; IRRADIATION; RADIOTHERAPY; TOXICITY; TUMORS;

PHYSICAL THERAPY;

CAPECITABINE; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANUS CARCINOMA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DOSE CALCULATION; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERKALEMIA; HYPONATREMIA; INFECTION; INGUINAL LYMPH NODE; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SIMULTANEOUS INTEGRATED BOOST INTENSITY MODULATED RADIATION THERAPY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DIARRHEA; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE FRACTIONATION; FATIGUE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOMYCIN; PAIN; POLYMORPHISM, GENETIC; RADIODERMATITIS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84875237986     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.12.008     Document Type: Article

References (20)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. L.G. Johnson, M.M. Madeleine, and L.M. Newcomer Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000 Cancer 101 2004 281 288
3. N.D. Nigro, V.K. Vaitkevicius, and B. Considine Jr. Combined therapy for cancer of the anal canal: a preliminary report Dis Colon Rectum 17 1974 354 356
4. UK Co-ordinating Committee on Cancer Research UKCCCR Anal Cancer Trial Working Party Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin Lancet 348 1996 1049 1054
5. H. Bartelink, F. Roelofsen, and F. Eschwege Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups J Clin Oncol 15 1997 2040 2049
6. M. Flam, M. John, and T.F. Pajak Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study J Clin Oncol 14 1996 2527 2539
7. F. Lim, and R. Glynne-Jones Chemotherapy/chemoradiation in anal cancer: a systematic review Cancer Treat Rev 37 2011 520 532
8. D.C. Weber, J.M. Kurtz, and A.S. Allal The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy Int J Radiat Oncol Biol Phys 50 2001 675 680
9. J.G. Bazan, W. Hara, and A. Hsu Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal Cancer 117 2011 3342 3351
10. N. Sawada, T. Ishikawa, and F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
11. B. Lengelé, and P. Scalliet Anatomical bases for the radiological delineation of lymph node areas. Part III: pelvis and lower limbs Radiother Oncol 92 2009 22 33
12. C.S. Yu, T.W. Kim, and J.H. Kim Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer Int J Radiat Oncol Biol Phys 67 2007 1020 1026
13. B. Reigner, K. Blesch, and E. Weidekamm Clinical pharmacokinetics of capecitabine Clin Pharmacokinet 40 2001 85 104
14. L.D. Vainchtein, H. Rosing, and J.H. Schellens A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma Biomed Chromatogr 24 2010 374 386
15. A. Ruzzo, F. Graziano, and K. Kawakami Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy J Clin Oncol 24 2006 1883 1891
16. C.B. Ambrosone, C. Tian, and J. Ahn Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study Breast Cancer Res 8 2006 R40 10.1186/bcr1526
17. M.J. Deenen, J. Tol, and A.M. Burylo Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer Clin Cancer Res 17 2011 3455 3468
18. T.M. Zagar, C.G. Willett, and B.G. Czito Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes Oncology (Williston Park) 24 2010 815 823
19. R. Glynne-Jones, H. Meadows, and S. Wan EXTRA - a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer Int J Radiat Oncol Biol Phys 72 2008 119 126
20. G.M. Freedman, N.J. Meropol, and E.R. Sigurdson Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer Int J Radiat Oncol Biol Phys 67 2007 1389 1393